Gaviscon Extra Peppermint Chewable Tablets 24s
2 Way Action Against Heartburn and Indigestion
Gaviscon Extra Chewable tablets are flat, circular, bi-layer tablets with a peppermint flavour. Each tablet contains 250mg Sodium Alginate, 106.5mg Sodium Bicarbonate and 187.5mg Calcium Carbonate. This medicine is used for the treatment of acid related symptoms of gastro-oesophageal reflux such as acid regurgitation, heartburn and indigestion which may occur, for example, following meals or during pregnancy. They work in 2 ways: a combination of two antacids to neutralise excess stomach acid, and an alginate which forms a protective layer that floats on top of the stomach contents, keeping it away from the lining of the food pipe.
Suitable for: Adults and children over 12 years. Can be used during pregnancy or breast-feeding. Children under 12 years: should only be given on medical advice.
Warnings and precautions: This product is high in sodium.If you have phenylketonuria, note that the product is sweetened with aspartame, a source of phenylalanine. Contains carmoisine lake (E122) which may cause allergic reactions. Consult your doctor if you are over 40 years and have never suffered with heartburn and acid indigesion before.If symptoms persist after 7 days, please consult your doctor.
How to use: Adults and children over 12 years: 2-4 tablets after meals and at bedtime.Read the package leaflet before use.
Storage instructions: Do not store above 30°C. Store in the original package to protect from moisture.
Ingredients: Each chewable tablet contains 250mg sodium alginate, 106.5mg sodium bicarbonate and 187.5mg calcium carbonate. The other ingredients are xylitol, carmellose sodium, magnesium sterate, macrogol 20,000, mannitol (E421), copovidone, acesulfame-k, aspartame (E951), mint flavour and carmoisine lake (E122). This product does not contain gluten.
Gaviscon Extra Chewable Tablets contains Sodium Alginate, Sodium Bicarbonate and Calcium Carbonate for heartburn and indigestion. ALWAYS READ THE LABEL. Date of preparation: Feb 2021. RB-M-33964